APA (7th ed.) Citation

Teichner, P., Cutrell, A., D'Amico, R., Dorey, D., Griffith, S., Harrington, C. M., . . . Shaefer, M. S. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases, 6, S20. https://doi.org/10.1093/ofid/ofz359.043

Chicago Style (17th ed.) Citation

Teichner, Paula, et al. "884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies." Open Forum Infectious Diseases 6 (2019): S20. https://doi.org/10.1093/ofid/ofz359.043.

MLA (9th ed.) Citation

Teichner, Paula, et al. "884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies." Open Forum Infectious Diseases, vol. 6, 2019, p. S20, https://doi.org/10.1093/ofid/ofz359.043.